Mycopathologia

, Volume 68, Issue 3, pp 179–181 | Cite as

Immunization of mice with an avirulent pseudohyphal form of Cryptococcus neoformans

  • Robert A. Fromtling
  • Rebecca Blackstock
  • Nancy K. Hall
  • Glenn S. Bulmer
Article

Abstract

Mice were immunized with a viable, avirulent strain ofCryptococcus neoformans. Lymphocyte blastogenic assays showed a 10-fold increase in reactivity of sensitized spleen cells, and histopathologic examination revealed marked splenic hyperplasia. Thirty-two days after intravenous inoculation with a virulent strain ofC. neoformans, none of the control animals survived whereas 60 percent of the immunized mice were alive with no clinical evidence of disease. This animal model shows that protective immunity can be established, and once developed, provide a better model for the study of important aspects of immunity in fungal disease.

Keywords

Animal Model Control Animal Clinical Evidence Histopathologic Examination Virulent Strain 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Diamond, R.D., and J.E. Bennett. 1973. Disseminated cryptococcosis in man: decreased lymphocyte transformation in response to Cryptococcus neoformans. J. Infect. Dis. 127: 694.Google Scholar
  2. 2.
    Gadebusch, H.H. 1958. Passive immunization against Cryptococcus neoformans. Proc. Soc. Exp. Biol. Med. 98: 611.Google Scholar
  3. 3.
    Louria, D.B. 1960. Specific and nonspecific immunity in experimental cryptococcosis in mice. Amer. Rev. Respir. Dis. 111: 643.Google Scholar
  4. 4.
    Hoff, C.L. 1942. Immunity studies of Cryptococcus hominis (Torula histolytica) in mice. J. Lab. Clin. Med. 27: 751.Google Scholar
  5. 5.
    Marcus, S., & F.R. Rambo. 1955. Immunity in Cryptococcosis. Proc. Soc. Amer. Bacteriol. 8: 92.Google Scholar
  6. 6.
    Kligman, A.M. 1947. Studies on the capsular substance of Torula histolytica and the immunological properties of Torula cells. J. Immunol. 57: 395.Google Scholar
  7. 7.
    Beemer, A.M., W. Davidson, E.S. Kuttin, Y. Zydon, & M. Pinto. 1976. Vaccine and mycostatin in treatment of cryptococcosis of the respiratory tract. Sabouraudia 14: 171.Google Scholar
  8. 8.
    Karaoui, R.M., N.K. Hall, & H.W. Larsh. 1977. Role of macrophages in immunity and pathogenesis of experimental cryptococcosis induced by the airborne route — Part I: pathogenesis and acquired immunity of Cryptococcus neoformans. Mykosen 20: 380.Google Scholar
  9. 9.
    Graybill, J.R., & R.L. Taylor. 1978. Host defense in cryptococcosis. I. An in vivo model for evaluating immune response. Inter. Arch. Allergy Appl. Immunol. 57: 101.Google Scholar
  10. 10.
    Catalona, W.J., J.L. Tarpley, C. Potvin, & P.B. Chretien. 1975. Correlations among cutaneous reactivity to DNCB, PHA induced lymphocyte blastogenesis and peripheral blood E rosettes. Clin. Exp. Immunol. 19: 326.Google Scholar
  11. 11.
    Neilson, J.B., M.H. Ivey, & G.S. Bulmer. 1978. Cryptococcus neoformans: Pseudohyphal forms surviving culture with Acanthamoeba polyphaga. Infect. Immun. 20: 262.Google Scholar
  12. 12.
    Blackstock, R., R.D. Schimpff & R.T. Smith. 1978. Heterogeneity of KCl-solubilized antigens of chemically induced sarcomas. Proc. Soc. Exp. Biolo. Med. 157: 354.Google Scholar
  13. 13.
    Hall, N.K., F. Deighton, & H.W. Larsh. 1978. Use of an alkali-soluble water-soluble extract of Blastomyces dermatitidis yeast-phase cell walls and isoelectrically focused components in peripheral lymphocyte transformations. Infec. Immun. 19: 411.Google Scholar

Copyright information

© Dr. W. Junk bv - Publishers 1979

Authors and Affiliations

  • Robert A. Fromtling
    • 1
  • Rebecca Blackstock
    • 2
  • Nancy K. Hall
    • 3
  • Glenn S. Bulmer
    • 1
  1. 1.Department of Microbiology and ImmunologyThe University of Oklahoma Health Sciences Center (OUHSC)Oklahoma CityUSA
  2. 2.Department of PediatricsOUHSCUSA
  3. 3.Department of PathologyOUHSCUSA

Personalised recommendations